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Abstract 
Background: We hypothesized that frailty acts as a measure of health outcomes in the context of LT. The aim of this 
study was to explore frailty index across LT, as a measure of morbidity and mortality. This was a retrospective observa-
tional study including all consecutive 47 HIV+patients who received LT in Modena, Italy from 2003 to June 2015.
Methods: frailty index (FI) was constructed from 30 health variables. It was used both as a continuous score and as 
a categorical variable, defining ‘most frail’ a FI > 0.45. FI change across transplant (deltaFI, ΔFI) was calculated as the 
difference between year 1 FI (FI–Y1) and pre-transplant FI (FI–t0). The outcomes measures were mortality and “otpimal 
LT” (defined as being alive without multi-morbidity).
Results: Median value of FI–t0 was 0.48 (IQR 0.42–0.52), FI–Y1 was 0.31 (IQR 0.26–0.41). At year five mortality rate was 
45%, “optimal transplant” rate at year 1 was 38%. All the patients who died in the post-LT were most frail in the pre-LT. 
ΔFI was a predictor of mortality after correction for age and MELD (HR = 1.10, p = 0.006) and was inversely associated 
with optimal transplant after correction for age (HR = 1.04, p = 0.01).
Conclusions: We validated FI as a valuable health measure in HIV transplant. In particular, we found a relevant cor-
relation between FI strata at baseline and mortality and a statistically significant correlation between, ΔFI and survival 
rate.
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Background
Liver transplantation (LT) is theoretically the best treat-
ment for patients with end stage liver disease (ESLD) but 
its effectiveness is limited by short-term mortality and 
morbidity, and by persistent shortage of donors’ organs. 
Specific selection policies have been developed to iden-
tify good candidates for this surgical option [1, 2]. In 
this context, recipients with chronic health conditions, 
including HIV [3–6], can be admitted to this surgical 
procedure after appropriate selection.
Under the current medical urgency-based selection 
system, patients with worst outcomes while on the wait-
ing list, are given highest priority for LT [7] using model 
for end-stage liver disease (MELD) score [8], acting as a 
predictor of mortality in waiting list period. Unluckily 
this algorithms fails to depict the extremely relevant het-
erogeneity of morbidity and quality of life of patients in 
the post-LT period [9, 10]. In addition, in HIV settings, 
and in particular in HIV/HCV co-infected patients, the 
prognostic value of the MELD score is uncertain. Some 
studies [11, 12] found a significant correlation between 
MELD and post-LT mortality, whereas in others this 
model had limited prognostic value [13, 14].
Frailty, conceptualized as frailty phenotype [15] or as 
an accumulation of deficit measure in a Frailty Index (FI) 
score [16], has the potential to predict relevant post-LT 
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outcomes and assess the overall health status of the 
candidates.
Frailty phenotype in the HIV negative solid organ 
transplant population has been proven to be associated 
with increased mortality, early hospital readmission, 
delayed graft function after kidney transplant [17–20] 
and poor health outcomes in liver disease patients [21–
24], including LT waitlist mortality [24].
Derck et al. [23], recently showed that frailty phenotype 
outperformed MELD in predicting quality of life in the 
pre-transplant period.
Moreover, Wilson et al. [25] demonstrated the predic-
tive power of pre-transplant FI on post-transplant mor-
tality in the setting of lung transplant.
Finally, Lai et  al. [26] showed an association between 
measures of physical function related to frailty and post-
LT mortality.
Frailty Index (FI) describes a multidimensional risk 
state which summarizes health deficits across a range 
of symptoms, signs, diseases, disabilities and laboratory 
abnormalities [16, 27]. This approach is robust across 
different settings, in different populations, using differ-
ent numbers and types of health variables, consistently 
related to age and to adverse outcomes. Notably, this pre-
dictive capacity transferred into a scale measure (index) 
can be used in clinical practice to monitor health tran-
sition over time and in relation to medical interventions 
[28].
Our group have previously validated a FI in HIV-pos-
itive patients to measure biological aging, health status 
and prediction of mortality and multi-morbidity (MM) 
incidence [29, 30]. We decided to expand this experience 
in the context of LT in HIV patients. In this peculiar set-
ting patient selection is more stringent due to the higher 
risk of morbidity and mortality of this vulnerable popula-
tion [31].
We hypothesized that frailty, conceptualised as a deficit 
accumulation, acts as a measure of health outcomes that 
covers the overall LT process.
The aim of this study was to explore frailty index (FI) 
across LT, as a measure of morbidity and mortality.
Methods
Retrospective observational study including all consecu-
tive HIV infected patients who received cadaveric donor 
liver transplant at the Liver and Multivisceral Transplant 
Center of University of Modena and Reggio Emilia from 
June 2003 to June 2015.
Baseline data included demographics (ethnic origin, 
gender and age), HIV characteristics (transmission risk 
factors, duration of HIV infection, HIV CDC classifica-
tion, nadir CD4 cell count, class type and exposure to 
antiretroviral therapy, plasma HIV genotypic resistance 
assay antecedent or concomitant to switching and cur-
rent HAART) and ESLD history (aetiology, known 
duration of cirrhosis, HCV genotype, baseline serum 
HCV–RNA VL, previous cirrhotic decompensation epi-
sodes and presence of histologically documented hepato-
cellular carcinoma).
Donor risk index (DRI), comprising the following varia-
bles: donor age, donation after cardiac death, split/partial 
grafts, African-American race, less height, cerebrovas-
cular accident and ‘other’ causes of brain death, location 
and cold time, was retrospectively calculated as a charac-
teristics associated with liver graft failure but was not a 
graft allocation criteria [32].
Outcomes
Outcome measures considered in this cohort were:
1. Mortality: vital status was regularly updated at Liver 
and Multivisceral Transplant Center of University of 
Modena and Reggio Emilia via telephone contact and 
hospital records.
2. Optimal transplant: per protocol was defined as 
the post-LT survival of the patient in the absence 
of multi-morbidity. Multi-morbidity (MM) was 
described as the presence of three or more of the 
following six comorbidities: cardiovascular disease 
(clinical diagnosis with history of myocardial infarc-
tion, stroke, revascularization, or peripheral artery 
disease); hypertension (blood pressure measured 
twice ≥140  mmHg systolic or ≥90  mmHg diastolic 
or taking antihypertensive medicine); type two dia-
betes mellitus (measured fasting glucose  ≥126 or 
oral glucose tolerance test  >200 or on treatment); 
chronic kidney disease (estimated glomerular filtra-
tion rate  <60  mL/min, via Modification of Diet in 
Renal Disease study equation [33]); osteopenia (dual-
energy X-ray absorptiometry t or z score  <−1.5) or 
osteoporosis (dual-energy X-ray absorptiometry 
t or z score  <−2.5 or fragility fracture); or dyslipi-
demia (total cholesterol  >200  mg/dL or low-density 
lipoprotein  >100  mg/dL or high-density lipopro-
tein  >100  mg/dL or triglycerides  >150  mg/dL). 
COPD was not included as it is an exclusion criteria 
for liver transplant [34].
Non-optimal transplant was defined as the absence of 
optimal transplant, due to mortality or MM.
Predictors
Frailty index: was built, as previously described [29] to 
calculate the proportion of health deficits individuals 
have accumulated out of a group of 30 relatively nonspe-
cific health variables (Table  1). Each variable included 
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was recorded with values of one when a deficit was pre-
sent, and zero when absent [35]. Missing values were 
removed from both numerator and denominator of the 
FI (FI = 
∑
Deficit
30−
∑
Missingvalues
).
Study visits were applicable for FI evaluation if they had 
at least 80% of available health variables at that visit.
According to literature [36], we classified as “most frail” 
in a particular moment patients with FI > 0.45, as “frail” 
persons with FI between 0.21 and 0.45 and as “fit” or “not 
frail” people with FI < 0.21.
It must be noticed that in the risk prediction of “opti-
mal/non-optimal transplant” a modified version of FI not 
listing the 6 comorbidities used to define MM, was used 
to avoid overlap between predictive variables and study 
outcome.
Frailty was assessed pre-LT (baseline) and at year 1, 3 
and 5. Patients who died or did not reach year 1 post-LT 
censored FI data at last available assessment.
Pre-transplant FI (FI–t0) was calculated at the last 
available data before transplant (baseline visit), within 
30 days before LT.
Post-LT FI was assessed at a median period of 262 days 
(IQR  =  87–324) at year 1 visit (FI–Y1), at a median 
period of 1090  days (IQR  =  1028–1142) at year 3 visit 
(FI–Y3) at a median period of 1843 days (IQR = 1800–
1877) at year 5 visit (FI–Y5).
FI change across transplant ( ΔFI), was calculated as 
the score difference between FI–Y1 and FI–t0.
We assessed FI validity using a three part approach that 
comprehends content, construct, and criterion validity as 
previously described [29, 37].
Other predictors at transplant time were: donor risk 
index, gender, age, BMI, MELD HCV antibody and RNA 
detectability, CD4 nadir and current, history of AIDS 
conditions and HIV viral load.
Statistical analysis
Descriptive statistics and FI scores at the baseline were 
calculated and distributions visualized. Cross-sectional 
relationships between FI scores and years of age were 
evaluated by linear regression. For prediction models, 
frailty index score was categorized using 0.1 increment. 
Each covariate was evaluated in univariate prediction 
models due to the small sample size and the low rate of 
events.
Mortality: Kaplan–Meier approach was used to evalu-
ate mortality. Univariate Cox regression analysis was 
used to assess factors associated with mortality. We 
also calculated mortality in the 3 categorical frailty 
strata.
Unsuccessful LT: Multivariate analysis was used to 
assess the association between FIt0 and non-optimal 
transplant, FIY1 and non-optimal transplant, correct-
ing for age. A Univariate Poisson analysis was used to 
assess the association between the 3 frailty strata at 
the baseline and non-optimal transplant.
FI = FIY 1− FIt0
Table 1 Variables included in the Frailty Index
Nr. Variable Deficit description
1 Hypertension Measured blood pressure or on 
treatment
2 Diabetes mellitus type II Fasting glucose >125 mg/dL or 
on treatment
3 Chronic kidney disease Two estimated glomerular 
filtration rate measure-
ments <60 mL/min/1.73 m2
4 Osteopenia/Osteoporosis Osteopenia: dual-energy X-ray 
absorptiometry (DEXA) Tor Z 
score <−1.5 or Osteoporosis: 
DEXA Tor Z score <−2.5 or 
fragility fracture
5 Any cancer Clinical diagnosis
6 High or low BMI <18 or >25 kg/m2
7 High total cholesterol >200 mg/dL
8 High triglycerides >150 mg/dL
9 Leucopenia <4000 cells/µL
10 Anemia If female: <10 g/dL
If male: <12 g/dL
11 Low platelets <150 billion/L
12 Hyponatremia <125 mEq/L
13 Abnormal potassium <3.5 or >5.3 mEq/L
14 Elevated aspartate transaminase >31 U/L
15 Elevated alanine transaminase >31 U/L
16 Abnormal alkaline phosphatase <38 or >126 U/L
17 Elevated γ-glutamyl  
transphosphatase
>55 U/L
18 Elevated total bilirubin >1.10 mg/dL
19 Elevated creatinine If female: >1.0 mg/dL
If male: >1.2 mg/dL
20 Elevated INR >1.2
21 Hepatits C virus viral load HCV-RNA >12 copies/mL
22 Hepatitis B coinfection Pre-LT: positive HBeAg
Post-LT: HBV-DNA >copies/mL
23 Epstein-Barr virus coinfection Pre-LT: positive EBV IgG
Post-LT: HBV-DNA >copies/mL
24 Cytomegalovirus coinfection Pre-LT: CMV IgG
Post-LT: HBV-DNA >copies/mL
25 HIV viral load >40 copies/µL
26 Current  CD4+ cell count <500 cells/µL
27 CD4+/CD8+cell ratio <1
28 Nadir  CD4+ cell count <200 cells/µL
29 History of AIDS History of CDC category C HIV 
disease [38]
30 Duration of HIV infection at LT >20.6 years
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Health transition after LT: FI was used to evaluate 
health transition after LT. LOWESS smoother graphs 
were drawn to describe FI over time. A linear regres-
sion model was used to determine the association 
between FI–t0 and, ΔFI at the year 1, year 3 and year 
5 visit. The same method was used to determine the 
association between FI–t0 and FI–Y1.
Results
Population characteristics at baseline
Forty-seven HIV-positive patients underwent LT at Liver 
and Multivisceral Transplant Center of University of 
Modena and Reggio Emilia since from 2003 to June 2015. 
Among them, 5 underwent simultaneous transplant of 
liver and kidney.
Most LT patients were males (80.8%) with a median age 
of 51.2 years; IQR = 45.91–54.35).
Median pre-transplant  CD4+ count was 260 cells/µL 
(IQR 153–360 cells/µL), with only 9 patients (17%) hav-
ing a CD4 count above 500 cells/µL. Most of the patients 
(44; 93.6%) presented undetectable HIV-RNA at trans-
plant time.
Median baseline frailty index was 0.48 (IQR 0.42–0.52).
Liver transplant indications
The most common indication for liver transplant was 
HCV-induced ESLD (82.9%), followed by hepatocellu-
lar carcinoma (HCC; 44.6%). Twenty-eight patients pre-
sented multiple indications, in particular, two of them 
had four indications (association of HCV, HBV, HDV 
and HCC in both cases), six had three indications and 20 
had two indications. Among this latter group, the most 
prevalent association (60%) was HCV and HCC. Median 
pre-transplant MELD was 22 (IQR 16.5–29).
Mortality
Mortality at year five post-LT was 45%, while at year 1 
and year 3 was respectively 21 and 38%.
A multivariate analysis including all baseline FI vari-
ables was performed, but none of them reached statistical 
significance in predicting post-transplant mortality.
Figure  1 describes how mortality was related to HCV 
antibody status and HCV RNA detectability at transplan-
tation. Of interest, seven HCV + patients were treated in 
the pre-LT with HCV directly active agents (DAA) and 
none of them died in the 1-year follow up.
Optimal transplant/Non‑optimal transplant
Prevalence of MM was fairly stable in the post-LT period, 
respectively prevalent in 39, 46 and 38% at year 1, 3 and 5.
As reported in Additional file 1: Figure S1 the propor-
tion of survivors with no MM, who met the definition of 
“Optimal transplant”, were respectively 38% (17 patients) 
at year 1, 29% (10) at year 3 and 26% (8) at year 5.
Frailty index
Construct validity: frailty index description
Pre-transplant frailty index ranged from 0.32 to 0.62, 
with a median of 0.48 (IQR 0.42–0.52). Consistently 
with literature [29, 35, 38, 39], its upper limit was close 
to 0.7. It was significantly associated with age (r = 0.30, 
p = 0.048) and followed a normal distribution. At base-
line 29 patients (61.7%) were classified as “most frail”, 
whilst 18 (38.3%) were “frail” and no one was “not frail”.
No significant correlation was observed between base-
line FI and pre-transplant MELD (r =  0.14, p =  0.932). 
Pre-LT frailty index was conversely correlated with donor 
risk index [32] (DRI) (r = −0.50; p = 0.008).
Criterion validity: DELTA FI ability to predict major outcomes
Baseline FI, analysed into 0.1 increment was not signifi-
cantly associated with survival (HR  =  1.47; p  =  0.90). 
However, all the 10 deceased patients (100%) at year 1 
were “most frail” at baseline (HR and p value are not sta-
tistically applicable in this situation).
FI at year 1 was associated with mortality after correc-
tion for age (HR = 1.12, p = 0.04) or for FIt0 (HR = 1.13, 
p = 0.03).
Univariate Poisson regression analysis of the associa-
tion between non-optimal transplant and frailty strata 
at the baseline showed an IRR = 1.45 (CI   0.7078–2.98; 
p = 0.3).
Figure 2 shows that ΔFI at multivariate Cox regression 
was a predictor of mortality after correction for age and 
MELD (HR =  1.10, p =  0.006) as well as a predictor of 
non-optimal transplant at multivariate Poisson regres-
sion after correction for age (HR = 1.04, p = 0.01).
Fig. 1 Kaplan–Meier survival estimate in relation to HCV RNA at the 
time of transplantation
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Frailty index to describe health transition across liver 
transplant
Survivors and deceased patients showed a different pat-
tern FI reduction post-LT. This is visually depicted in 
Fig.  3 by a LOWESS smoother of the FI in function of 
time and describes a different health transition across LT 
in the two groups.
Among the 29 most frail patients at the baseline, dur-
ing the first year post-LT 10 died, three remained stable 
and 16 improved (reverted from “most frail” to “frail”). In 
contrast, among the 18 patients who were “frail” at base-
line, 6 did not have enough data to calculate the Y1FI, 10 
remained stable and two reverted their condition to “non 
frail”. Notably, none of them worsened their “frail” status 
to “most frail”.
Baseline frailty index scores strongly influenced transi-
tion probabilities at year 1 (r = 0.37, p = 0.027).
Discussion
This study validates FI in HIV transplant setting and 
describes health status transition across the overall LT 
process.
In the pre-transplant assessment FI measurement 
(baseline FI) exhibited expected characteristics of the 
general population with regards to normal distribution, 
association with age and upper limit ceiling effect [29, 
40].
Of interest, baseline FI was conversely associated with 
DRI. This index can be considered a proxy of the “qual-
ity of the graft”. Thus, in our cohort better livers were 
allocated to patients with a higher FI, suggesting that 
baseline FI reflected the clinical judgment of vulnerabil-
ity that surgeons empirically consider when allocating 
organs, within the respect of urgency criteria established 
by MELD score.
With regards to criterion validity, baseline “most frail” 
condition was able to predict mortality and in the post-
LT, with 10 out 29 patients died at year 1 between the 
“most frail” group vs 0 out of 18 among the “frail” one. 
Moreover, FI at year 1 was able to independently predict 
mortality.
It must be noticed that in this cohort pre-LT MELD 
was not associated with neither post-LT mortality nor 
baseline FI. The MELD provide a parsimonious measure 
of liver-related health associated with pre-transplant out-
come, whereas FI is a copious measure of overall health 
throughout the transplant process. Thus, we believe that 
not only the use of FI in the LT setting has the potential 
Fig. 2 Independent predictors of survival and successful transplant
Fig. 3 LOWESS smoother: FI time course in survived and deceased. 
Red vertical line represents transplant date
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to be clinically useful for candidates selection and tar-
geted rehabilitation therapies, but also that it could be of 
particular interest in the HIV population, where a higher 
vulnerability is present, comorbidities are more prevalent 
and where MELD is often less meaningful.
Unfortunately, even though the IRR of the association 
between optimal transplant and “most frail” condition at 
the baseline is consistent with the survival analysis, baseline 
FI was not significantly able to predict optimal transplant. 
However, its significant association with Y1FI suggests that 
this could be explained with a lack of statistical power due 
to the small sample size of this unique cohort.
In addition, we used our FI the health transition across 
the LT period. As shown in Fig. 3, frailty reduction was 
present in both deceased and survived patients, but the 
slope was more evident in the latter group. This picture is 
consistent with the FI change observed in HIV-negative 
elderly population where frailty reduction was associated 
with improved survival [41, 42].
ΔFI is an interesting clinical conceptualization given 
that it allows considering a health status measure as the 
net change of biological events happening across LT, 
therefore taking in consideration in the same measure 
patient vulnerability both in the pre and in the post LT 
period. Applicability of FI in this clinical setting may also 
offer a measure of intensity of care giving insight in the 
large variability of health status in the post-LT.
ΔFI beyond year 1 was associated with both mortality 
and non-optimal transplant outcome, after correction 
for baseline confounders. Δ FI describes health transi-
tion across transplant, visually depicted by the LOWESS 
smoother curve. Mitnitski et  al. [16, 43, 44] state that 
frailty can be considered a proxy of biological age, thus, 
this findings quantifies the empirical perception of both 
patients and physicians that LT “puts the biological clock 
back” to the time before ESLD.
On a clinical standpoint, monitoring FI and delta FI 
after transplant can be useful. In particular, for patients 
that experienced less FI improvement more frequent fol-
low-up appointments can be considered or hospital dis-
charge should be delayed.
Some limitations can be acknowledged. The retrospective 
observational nature of the study avoided the possibility to 
expand FI variable list, which were close to the minimum 
number suggested for a FI validation. In particular, our FI 
lacks of patient-related outcome and geriatric syndrome 
evaluation usually part of geriatric FI variable lists.
The relatively small sample size of our cohort could be 
responsible of low statistical power of multivariable anal-
ysis not reaching statistical significant value.
Some strength points may also be recognised:
The validation of FI in the transplant setting provide a 
new biological variable able to capture not only recipient 
vulnerability and surgical risk but also describe health 
transition across LT.
Frailty could play a role in a “blended principle model” 
[1] of organ allocation, as it is able to assess patients’ 
overall health status and at the same time potential to be 
a predictor of both mortality and quality of life [23].
This approach also allows to link health status with bio-
logical age conceptualization: at an individual basis, LT 
is a turning point, with different perspective in patients 
and physicians. Patients often describe LT as a “re-birth”, 
meaning the biological and psychological aspect related 
to a new donated life. Along with the obvious psychologi-
cal benefit of passing from facing death to a longer life 
expectancy, the health and liver-related symptoms gain 
after LT reflects in a well-documented improvement in 
health [45–48]. Physicians often describe LT as a “reverse 
time” story, somehow putting back the biological clock 
to the time before ESLD. Both “re-birth”, and “reverse 
time” refer to the biological age categories, which can be 
depicted in the frailty assessment. This approach depict-
ing health transition across the transplant period allows 
interpreting LT as a time reversing event measuring 
health improvement.
We hope these results may pilot future studies to com-
pare different tools to evaluate frailty in the transplant 
setting and to expand the validation of FI toward other 
transplant settings.
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